Cargando…
Trends in clinical development of pediatric cancer for PD-1 and PD-L1 inhibitors: an analysis of ClinicalTrials.gov
Compared with cytotoxic chemotherapy, radiotherapy, and surgery, positive findings have been acquired through the approach of blocking the programmed cell death protein 1 (PD-1) pathway with antibodies that exert inhibitory effects on PD-1 or cell death protein ligand 1 (PD-L1). Results from clinica...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8479973/ https://www.ncbi.nlm.nih.gov/pubmed/34583971 http://dx.doi.org/10.1136/jitc-2021-002920 |
_version_ | 1784576375345119232 |
---|---|
author | Que, Yi Hu, Yang Hong, Dongchun Zhang, Yizhuo |
author_facet | Que, Yi Hu, Yang Hong, Dongchun Zhang, Yizhuo |
author_sort | Que, Yi |
collection | PubMed |
description | Compared with cytotoxic chemotherapy, radiotherapy, and surgery, positive findings have been acquired through the approach of blocking the programmed cell death protein 1 (PD-1) pathway with antibodies that exert inhibitory effects on PD-1 or cell death protein ligand 1 (PD-L1). Results from clinical trials showed great potential in adult patients with cancers, such as melanoma, non-small cell carcinoma, and nasopharyngeal carcinoma. However, studies of checkpoint inhibitors specifically targeting PD-1/PD-L1 in pediatric patients are limited. We evaluated ongoing clinical trials using PD-1 or PD-L1 inhibitors alone or in combination with other therapies to treat pediatric cancer. The proportion of PD-1/PD-L1 combination clinical trials has increased since 2018; the three most common trials over the past 2 years used CTLA-4 monoclonal antibodies, chemotherapy, and therapies that target the vascular endothelial growth factor axis. This commentary aimed to provide trends and specific insights into methods for conducting clinical trials of immunotherapy in the pediatric population. |
format | Online Article Text |
id | pubmed-8479973 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-84799732021-10-08 Trends in clinical development of pediatric cancer for PD-1 and PD-L1 inhibitors: an analysis of ClinicalTrials.gov Que, Yi Hu, Yang Hong, Dongchun Zhang, Yizhuo J Immunother Cancer Commentary Compared with cytotoxic chemotherapy, radiotherapy, and surgery, positive findings have been acquired through the approach of blocking the programmed cell death protein 1 (PD-1) pathway with antibodies that exert inhibitory effects on PD-1 or cell death protein ligand 1 (PD-L1). Results from clinical trials showed great potential in adult patients with cancers, such as melanoma, non-small cell carcinoma, and nasopharyngeal carcinoma. However, studies of checkpoint inhibitors specifically targeting PD-1/PD-L1 in pediatric patients are limited. We evaluated ongoing clinical trials using PD-1 or PD-L1 inhibitors alone or in combination with other therapies to treat pediatric cancer. The proportion of PD-1/PD-L1 combination clinical trials has increased since 2018; the three most common trials over the past 2 years used CTLA-4 monoclonal antibodies, chemotherapy, and therapies that target the vascular endothelial growth factor axis. This commentary aimed to provide trends and specific insights into methods for conducting clinical trials of immunotherapy in the pediatric population. BMJ Publishing Group 2021-09-28 /pmc/articles/PMC8479973/ /pubmed/34583971 http://dx.doi.org/10.1136/jitc-2021-002920 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Commentary Que, Yi Hu, Yang Hong, Dongchun Zhang, Yizhuo Trends in clinical development of pediatric cancer for PD-1 and PD-L1 inhibitors: an analysis of ClinicalTrials.gov |
title | Trends in clinical development of pediatric cancer for PD-1 and PD-L1 inhibitors: an analysis of ClinicalTrials.gov |
title_full | Trends in clinical development of pediatric cancer for PD-1 and PD-L1 inhibitors: an analysis of ClinicalTrials.gov |
title_fullStr | Trends in clinical development of pediatric cancer for PD-1 and PD-L1 inhibitors: an analysis of ClinicalTrials.gov |
title_full_unstemmed | Trends in clinical development of pediatric cancer for PD-1 and PD-L1 inhibitors: an analysis of ClinicalTrials.gov |
title_short | Trends in clinical development of pediatric cancer for PD-1 and PD-L1 inhibitors: an analysis of ClinicalTrials.gov |
title_sort | trends in clinical development of pediatric cancer for pd-1 and pd-l1 inhibitors: an analysis of clinicaltrials.gov |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8479973/ https://www.ncbi.nlm.nih.gov/pubmed/34583971 http://dx.doi.org/10.1136/jitc-2021-002920 |
work_keys_str_mv | AT queyi trendsinclinicaldevelopmentofpediatriccancerforpd1andpdl1inhibitorsananalysisofclinicaltrialsgov AT huyang trendsinclinicaldevelopmentofpediatriccancerforpd1andpdl1inhibitorsananalysisofclinicaltrialsgov AT hongdongchun trendsinclinicaldevelopmentofpediatriccancerforpd1andpdl1inhibitorsananalysisofclinicaltrialsgov AT zhangyizhuo trendsinclinicaldevelopmentofpediatriccancerforpd1andpdl1inhibitorsananalysisofclinicaltrialsgov |